Search
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A7906] The SYSADOA status suggested a pain relief and increased joint mobility after a relative long regular administration, as well as a long-lasting effect after the end of the treatment. … Chondroitin sulfate is a glycosaminoglycan considered as a symptomatic slow-acting drug for osteoarthritis (SYSADOA).
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigational[A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and
DL-dimyristoylphosphatidylcholine
go.drugbank.com/drugs/DB11283ApprovedA synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial drug preparations to solubilize drugs for injection
CHO Cells Recombinant Vaccine
go.drugbank.com/drugs/DB15893ExperimentalThis vaccine candidate, developed in China, uses SARS-CoV-2 protein subunits that are entirely engineered, created, and secreted by Chinese Hamster Ovary (CHO) cells[A219758].
Quinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigational[A184844] Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423] … [L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.
Spesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalIt is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.